Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nikky Bardia

Cardiovascular Disease Bakersfield, CA Medical Doctor

NPI 1932559978 CMS profile 4217185

2901 Sillect Ave Ste 100, Bakersfield, CA 93308

Open in the dashboard

General payments

$9,225

168 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nikky Bardia of Bakersfield, CA is reported in the CMS Open Payments database as having received $9,225 across 168 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,273 79
2024 General $4,818 76
2023 General $734 4
2022 General $199 4
2021 General $142 2
2019 General $59 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nikky Bardia
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Nikky Bardia were reported at $3,273. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Nikky Bardia Cardiovascular Disease median Middle half National median
2019 $59 $450 $127–$1,392 $163
2020 $0 $242 $77–$751 $114
2021 $142 $335 $101–$1,037 $132
2022 $199 $395 $121–$1,211 $149
2023 $734 $443 $136–$1,283 $160
2024 $4,818 $450 $136–$1,323 $164
2025 $3,273 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $2,931 53 payments
  2. Boston Scientific Corporation $1,918 17 payments
  3. Medtronic, Inc. $715 9 payments
  4. Abbott Laboratories $553 14 payments
  5. Cardiva Medical, Inc. $356 9 payments
  6. Penumbra, Inc. $315 3 payments
  7. Novo Nordisk Inc $267 4 payments
  8. Stryker Corporation $261 2 payments
  9. Amgen Inc. $222 4 payments
  10. Abiomed $177 6 payments
  11. Other $1,510 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,139 154 payments
  2. Travel and Lodging $2,334 8 payments
  3. Grant $1,063 1 payment
  4. Education $689 5 payments
Products named General payments · program years 2019–2025
  1. PASCAL $1,079 16 payments
  2. SAPIEN 3 Ultra RESILIA $500 35 payments
  3. ONYX FRONTIER $399 2 payments
  4. Indigo System $315 3 payments
  5. ENSITE $239 1 payment
  6. CT THROMBECTOMY SYSTEM KIT $188 3 payments
  7. FLOWTRIEVER CATHETER, S $188 3 payments
  8. LifeVest $171 6 payments
  9. KENGREAL $157 4 payments
  10. FFRct $156 2 payments
  11. Other $3,158 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Internal Medicine: 777

Drug cost

$196

Median for Internal Medicine: $73,373

Branded share of claims

100%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 14 $196

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $109
$109 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $106
$106 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $44
$44 — —
CLEVIPREX
  • CHIESI USA, INC. $42
$42 — —
KENGREAL
  • CHIESI USA, INC. $42
$42 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

168 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record